Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sodium channel regulatory subunit beta-2 (SCN2B)
- Target
- SCN2B
- Molecular classification
- Ion channel auxiliary/regulatory subunit, Membrane protein, Immunoglobulin superfamily (domain features)
01
Overview
Sodium channel regulatory subunit beta-2 (SCN2B) is a membrane protein encoded by the SCN2B gene in humans. It acts as an auxiliary regulatory subunit of multiple voltage-gated sodium channels (NaV), directly mediating membrane depolarization in excitable cells such as neurons, cardiac, muscle, and neuroendocrine cells. SCN2B modulates sodium channel localization and function, affecting action potential initiation and propagation, cell-cell adhesion, and migration. Defects in the SCN2B gene are implicated in diseases such as familial atrial fibrillation, Brugada syndrome, and sudden infant death syndrome.
- Other names
- Sodium voltage-gated channel beta subunit 2Sodium channel, voltage-gated, type II, beta polypeptideSodium channel, voltage-gated, type II, beta subunitSodium channel regulatory subunit beta-2Neuronal voltage-gated sodium channel beta 2 subunitSCN2BATFB14
02
Mechanism of action
Drugs act by inhibiting voltage-gated sodium channels, reducing sodium influx and excitability in tissues; the presence or mutation of SCN2B can modulate sensitivity and response to these drugs
03
Biological functions
Regulation of voltage-gated sodium channel activityModulation of membrane depolarization and action potential propagationCell-cell adhesionCell migration
04
Disease associations
Cardiovascular disease (atrial fibrillation, familial; Brugada syndrome)Sudden infant death syndromeNeurodegenerative disease (neuropathic pain—implicated via sodium channel pathways)
05
Safety considerations
Mutations can cause arrhythmias and sudden cardiac death; off-target effects of sodium channel blockers may exacerbate arrhythmogenic risk if SCN2B is dysfunctional
06
Interacting drugs
Lidocaine
5 more in the full profile.
07
Biomarkers
SCN2B gene mutations are potential biomarkers for familial atrial fibrillation and Brugada syndrome
Beyond the preview
Go deeper on Sodium channel regulatory subunit beta-2 (SCN2B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sodium channel regulatory subunit beta-2 (SCN2B).